When it comes to biotech buyouts, no one really knows anything
Every winter, Wall Street analysts survey investors about the year ahead. And pretty much every year, those investors forecast an uptick in acquisitions. They were right about 2019, which saw a roughly 30% jump in dealmaking compared with the last five years on average. But when it came to predicting which companies would get acquired, stock pickers didn’t fare so well.
Of the 10 most-likely-to-be-acquired companies on last year’s J.P. Morgan survey, only one, Tesaro, actually got bought. The list included Clovis Oncology, which is down about 40% on the year, and Sage Therapeutics, which has been cut in half since January.
With that in mind, the latest J.P. Morgan survey came out yesterday, and again the majority of respondents predicted an increase in buyout activity. The list of likely takeouts included UniQure, Amarin, and Sarepta Therapeutics, but you should perhaps take those with a grain of salt.
Of the 10 most-likely-to-be-acquired companies on last year’s J.P. Morgan survey, only one, Tesaro, actually got bought. The list included Clovis Oncology, which is down about 40% on the year, and Sage Therapeutics, which has been cut in half since January.
With that in mind, the latest J.P. Morgan survey came out yesterday, and again the majority of respondents predicted an increase in buyout activity. The list of likely takeouts included UniQure, Amarin, and Sarepta Therapeutics, but you should perhaps take those with a grain of salt.
.png)
No hay comentarios:
Publicar un comentario